Question 1

What is combined oxidative phosphorylation defect type 17?

Accepted Answer

Combined oxidative phosphorylation defect type 17 is a disorder of mitochondrial energy metabolism caused by mutations in the ELAC2 gene. It typically presents in infancy and early childhood, with affected individuals showing signs such as cardiomyopathy and developmental difficulties. The condition is very rare, affecting fewer than 1 in 1,000,000 people, and it involves multiple organ systems including both the heart and the central nervous system. Modern care strategies continue to advance our understanding and management of this complex disorder.

Question 2

What are the symptoms of combined oxidative phosphorylation defect type 17?

Accepted Answer

The clinical presentation of combined oxidative phosphorylation defect type 17 is multifaceted. Characteristic findings include hypertrophic cardiomyopathy and decreased activity of mitochondrial complex I, both of which are present in all affected individuals. Early features may involve intrauterine growth retardation and hypotonia, while later manifestations can include lactic acidosis, congestive heart failure, global developmental delay, and cognitive challenges. Additional variable features, observed in a subset of patients, include microcephaly, postnatal growth retardation, sensorineural hearing impairment, and failure to thrive. Not all individuals experience all features, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation defect type 17?

Accepted Answer

Combined oxidative phosphorylation defect type 17 is caused by mutations in the ELAC2 gene, which plays a role in mitochondrial function and energy production. The disorder is inherited in an autosomal recessive pattern, meaning that an affected individual inherits a mutated copy of the gene from each parent. This mode of inheritance is more common when parents share a common ancestor, as both are more likely to carry the same rare genetic variant, which underscores the importance of genetic counseling for families considering future pregnancies. Associated genes include ELAC2.

Question 4

How is combined oxidative phosphorylation defect type 17 inherited?

Accepted Answer

combined oxidative phosphorylation defect type 17 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is combined oxidative phosphorylation defect type 17?

Accepted Answer

combined oxidative phosphorylation defect type 17 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is combined oxidative phosphorylation defect type 17 diagnosed?

Accepted Answer

The definitive diagnosis of combined oxidative phosphorylation defect type 17 is achieved through molecular genetic testing that identifies pathogenic variants in the ELAC2 gene. Clinicians also rely on a comprehensive clinical evaluation, noting characteristic features such as hypertrophic cardiomyopathy, lactic acidosis, and global developmental delay, to support the diagnosis. Because these symptoms can overlap with those of other conditions, genetic testing is essential to distinguish this disorder from similar metabolic and mitochondrial diseases.

Question 7

Are there treatments for combined oxidative phosphorylation defect type 17?

Accepted Answer

Currently, management focuses on supportive care and symptom management because no foundational therapies or FDA-approved treatments are available for combined oxidative phosphorylation defect type 17. Treatment is individualized and typically involves a multidisciplinary team that may include cardiologists, metabolic specialists, and developmental pediatricians. Regular surveillance is an essential part of long-term care, helping to monitor cardiac function, metabolic status, and developmental progress. Patients and their families are encouraged to discuss treatment options and supportive strategies with their healthcare team and consider genetic counseling to understand implications for family planning.

Question 8

What complications can arise from combined oxidative phosphorylation defect type 17?

Accepted Answer

Complications from combined oxidative phosphorylation defect type 17 can include progressive issues such as congestive heart failure and lactic acidosis. Some individuals may also experience global developmental delays and cognitive challenges. The severity of these complications can vary widely among affected individuals, making regular monitoring and care essential.

Question 9

How does combined oxidative phosphorylation defect type 17 affect daily life for patients and families?

Accepted Answer

Living with combined oxidative phosphorylation defect type 17 can be challenging due to the need for ongoing medical care and support. Families may need to manage symptoms like hypotonia and developmental delays, which can impact daily activities and routines. It is important for families to work closely with a healthcare team to develop strategies that support the child's development and overall well-being.

Question 10

What is the prognosis for individuals with combined oxidative phosphorylation defect type 17?

Accepted Answer

The prognosis for individuals with combined oxidative phosphorylation defect type 17 varies greatly depending on the severity of symptoms and the age at which they are diagnosed. Many individuals can stabilize their symptoms with proper care, but some may face progressive complications over time. Ongoing management and support from specialists can help improve quality of life.

Question 11

What specialists should families consult for combined oxidative phosphorylation defect type 17?

Accepted Answer

Families dealing with combined oxidative phosphorylation defect type 17 should consider consulting a multidisciplinary team of specialists. This may include cardiologists for heart-related issues, metabolic specialists for managing energy metabolism, and developmental pediatricians to support growth and development. Regular check-ups with these experts can help monitor the child's condition and provide tailored care.

Kisho

combined oxidative phosphorylation defect type 17

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

combined oxidative phosphorylation defect type 17

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation defect type 17?

What are the symptoms of combined oxidative phosphorylation defect type 17?

What causes combined oxidative phosphorylation defect type 17?

How is combined oxidative phosphorylation defect type 17 inherited?

How rare is combined oxidative phosphorylation defect type 17?

How is combined oxidative phosphorylation defect type 17 diagnosed?

Are there treatments for combined oxidative phosphorylation defect type 17?

What complications can arise from combined oxidative phosphorylation defect type 17?

How does combined oxidative phosphorylation defect type 17 affect daily life for patients and families?

What is the prognosis for individuals with combined oxidative phosphorylation defect type 17?

What specialists should families consult for combined oxidative phosphorylation defect type 17?

Explore clinical features